• 1
    Brennan MF. Adrenocortical carcinoma. CA Cancer J Clin. 1987; 37: 348365.
  • 2
    Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer. 1993; 72: 31453155.
  • 3
    Demeure MJ, Somberg LB. Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies. Surg Oncol Clin N Am. 1998; 7: 791805.
  • 4
    Norton JA. Adrenal tumors. In: DevitaVTJr., HellmanS, RosenbergSA, editors. Cancer: principles and practice of oncology. 5th edition. Philadelphia: Lippincott-Raven, 1997: 16591669.
  • 5
    Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery. 1992; 112: 963970.
  • 6
    Bergenstal DM, Hertz R, Lipsett MB. Chemotherapy of adrenocortical cancer with o'p'DDD. Ann Intern Med. 1960; 53: 672682.
  • 7
    Hutter AM Jr., Kayhoe DE. Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients. Am J Med. 1966; 41: 581592.
  • 8
    Lubitz JA, Freeman L, Okun R. Mitotane use in inoperable adrenalcortical carcinoma. JAMA. 1973; 223: 11091112.
  • 9
    Nader S, Hickey RC, Sellin RV, et al. Adrenal cortical carcinoma. A study of 77 cases. Cancer. 1983; 52: 707711.
  • 10
    van Slooten H, Moolenaar AJ, van Seters AP,et al. The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol. 1984; 20: 4753.
  • 11
    Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer. 1993; 71: 31193123.
  • 12
    Samaan NA, Hickey RC. Adrenal cortical carcinoma. Semin Oncol. 1987; 14: 292296.
  • 13
    Decker RA, Elson P, Hogan TF, et al. Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery. 1991; 110: 10061013.
  • 14
    Haq MM, Legha SS, Samaan NA, et al. Cytotoxic chemotherapy in adrenal cortical carcinoma. Cancer Treat Rep. 1980; 64: 909913.
  • 15
    Ling V, Gerlach J, Kartner N. Multidrug resistance. Breast Cancer Res Treat. 1984; 4: 8994.
  • 16
    Flynn SD, Murren JR, Kirby WM, et al. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery. 1992; 112: 981986.
  • 17
    Haak HR, van Seters AP, Moolenaar AJ, et al. Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Eur J Cancer. 1993; 29A: 10361038.
  • 18
    Bates SE, Shieh CY, Mickley LA, et al. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab. 1991; 73: 1829.
  • 19
    Feller N, Hoekman K, Kuiper CM, et al. A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile. Cancer Res. 1997; 3: 389394.
  • 20
    Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990; 322: 11951201.
  • 21
    Robey R, Bakke S, Stein W, et al. Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. Blood. 1999; 93: 306314.
  • 22
    Anderson JR, Cain KC, Gelber RD, et al. Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials. Cancer Treat Rep. 1985; 69: 11391146.
  • 23
    Icard P, Chapuis Y, Andreassian B, et al. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery. 1992; 112: 972979.
  • 24
    Jensen JC, Pass HI, Sindelar WF, et al. Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy. Arch Surg. 1991; 126: 457461.
  • 25
    Bellantone R, Ferrante A, Boscherini M, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery. 1997; 122: 12121218.
  • 26
    Cai W, Counsell RE, Djanegara T, et al. J Metabolic activation and binding of mitotane in adrenal cortex homogenates. J Pharm Sci. 1995; 84: 134138.
  • 27
    Haak HR, Hermans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 1994; 69: 947951.
  • 28
    von Slooten H, van Seters AP, Smeenk D, et al. O,p'-DDD (mitotane) levels in plasma and tissues during chemotherapy and at autopsy. Cancer Chemother Pharmacol. 1982; 9: 8588.
  • 29
    Bukowski RM, Wolfe M, Levine HS, et al. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol. 1993; 11: 161165.
  • 30
    Williamson SK, Lew D, Miller GJ, et al. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer. 2000; 88: 11591165.
  • 31
    Fojo AT. Multidrug resistance in human tumors. Cancer Treat Res. 1989; 48: 2736.
  • 32
    Stewart A, Steiner J, Mellows G, et al. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res. 2000; 6(11): 41864191.
  • 33
    Dantzig AH, Shepard RL, Law KL, et al. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther. 1999; 290: 854862.
  • 34
    van Zuylen L, Sparreboom A, van der Gaast A,et al. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res. 2000; 4: 13651371.
  • 35
    Newman MJ, Rodarte JC, Benbatoul KD, et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res. 2000; 60: 29642972.